All In Biotech

Drug Trial Radar · NCT06847854

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

151

Actual

Start

Dec 8, 2022

Primary completion

Nov 16, 2026

Study completion Jan 18, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

Conditions

  • Diabetic Macular Edema

Interventions

  • RO7497372Drug

    RO7497372 will be administered as IVT injection as per the schedule specified in the arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to 28 Weeks
  2. Part 2: Number of Participants With Intraocular Inflammation (IOI) AEs as Reported by the InvestigatorTime frame: Baseline to Week 48
  3. Part 2: Number of Participants With Severe or Serious Drug-Related IOI AEsTime frame: Baseline to Week 48
  4. Part 2: Number of Participants With Occlusive Retinal Vasculitis AEs as Reported by the InvestigatorTime frame: Baseline to Week 48

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Retinal Consultants of AZ, Ltd

    Peoria, Arizona

  • Associated Retina Consultants

    Phoenix, Arizona

  • Arkansas Retina Research

    Little Rock, Arkansas

  • Global Research Management

    Glendale, California

  • Retinal Consultants Medical Group

    Modesto, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Florida Eye Associates

    Melbourne, Florida

  • Medeye Associates

    South Miami, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • Retina Specialists of Tampa

    Wesley Chapel, Florida

  • Center for Retina and Macula Disease

    Winter Haven, Florida

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Retina Associates of Michigan

    Grand Blanc, Michigan

  • Foundation for Vision Research

    Grand Rapids, Michigan

  • Retina Consultants Minnesota

    Saint Louis Park, Minnesota

  • Mississippi Retina Associates

    Madison, Mississippi

  • The Retina Institute

    St Louis, Missouri

  • Sierra Eye Associates

    Reno, Nevada

  • Ross Eye Institute

    Buffalo, New York

  • Retina Associates of NY

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Verum Research LLC

    Eugene, Oregon

  • EyeHealth Northwest

    Portland, Oregon

  • Erie Retinal Surgery

    Erie, Pennsylvania

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Carolina Eyecare Physicians

    Mt. Pleasant, South Carolina

  • Charles Retina Institute

    Germantown, Tennessee

  • Austin Clinical Research LLC

    Austin, Texas

  • Brown Retina Institute

    Schertz, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

  • Salt Lake Retina

    West Jordan, Utah

  • Retina Group of Washington

    Fairfax, Virginia

  • Emerson Clinical Research Institute

    Falls Church, Virginia

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Wagner Kapoor Institute

    Norfolk, Virginia

  • Spokane Eye Clinic

    Spokane, Washington

  • Emanuelli Research and Development Center LLC

    Arecibo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.